---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-241845"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:39:29.722050+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno reports positive Phase 3 results for DCCR in Prader-Willi; primary endpoint met (p=0.0022)

## Summary
- Primary endpoint: HQ-CT total score difference of 5.0 at week 16 (p=0.0022) favoring DCCR over placebo.
- Secondary endpoints (CGI-S, CGI-I) showed trends toward worsening in placebo group (p=0.08 and 0.09).
- DCCR well-tolerated; no serious adverse events or discontinuations in DCCR group.
- Positive data triggers $15M warrant exercise (8.6M shares at $1.75) within 30 days by Nantahala, Abingworth, Vivo.
- Company targets NDA submission for DCCR in PWS mid-2024; FDA previously acknowledged potential for NDA support.

## SEC filing metadata
- accession: 0001193125-23-241845
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523241845/0001193125-23-241845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523241845/d486361d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-241845
- JSON: https://secwatch.observer/filing/0001193125-23-241845.json
- Plain text: https://secwatch.observer/filing/0001193125-23-241845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.